Legend Biotech Corporation Share Price & Technical Analysis
LEGN · $29.37 (+4.93%)
Healthcare / Biotechnology
$29.37
+4.93%
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multi…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
26% return in May, -10% avg return in past 3 year May month.
40% return in 2026, -17% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -20% | 9% | -2% | 28% | 26% | – | – | – | – | – | – | – | 40% |
| 25 | 16% | -6% | -4% | 2% | -16% | 23% | 9% | -9% | -7% | -2% | -14% | -21% | -29% |
| 24 | -7% | 18% | -14% | -24% | -8% | 11% | 26% | 2% | -14% | -8% | -7% | -23% | -47% |
| 23 | 1% | -10% | 3% | 46% | -6% | 6% | 10% | -8% | -3% | -2% | -9% | -1% | 27% |
| 22 | -9% | -7% | -11% | 7% | 4% | 28% | -14% | -1% | -11% | 22% | 2% | -2% | 7% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Emerging · Strong
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$4.90B
P/E ratio
—
52W high
$45.30
52W low
$16.24
Volume
20,49,729
Beta
0.30
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Legend Biotech Corporation share price today?
- Legend Biotech Corporation (LEGN) last traded around $29.37 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does LEGN have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for LEGN. Download the app for real-time alerts.
- How can I analyze Legend Biotech Corporation stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.